Polypills: an essential medicine for cardiovascular disease

Editorial

The Lancet. Lancet. 2017.

. 2017 Mar 11;389(10073):984.

doi: 10.1016/S0140-6736(17)30695-5.

No abstract available

Comment in

Are ACE inhibitors acceptable ingredients in polypills?
Messerli FH, Bangalore S, Rimoldi SF, Gąsowski J, Nussberger J. Messerli FH, et al. Lancet. 2017 Jul 1;390(10089):26. doi: 10.1016/S0140-6736(17)31468-X. Lancet. 2017. PMID: 28677554 No abstract available.

Uses of polypills for cardiovascular disease and evidence to date.
Huffman MD, Xavier D, Perel P. Huffman MD, et al. Lancet. 2017 Mar 11;389(10073):1055-1065. doi: 10.1016/S0140-6736(17)30553-6. Lancet. 2017. PMID: 28290995 Review.
Putting polypills into practice: challenges and lessons learned.
Webster R, Castellano JM, Onuma OK. Webster R, et al. Lancet. 2017 Mar 11;389(10073):1066-1074. doi: 10.1016/S0140-6736(17)30558-5. Lancet. 2017. PMID: 28290996 Review.